CG Oncology Stock Targeted for 137% Surge by Guggenheim Analysts
Table of Contents
Guggenheim’s initiation of coverage for CG Oncology with a $90 price target signals significant potential for the biopharmaceutical company, suggesting a possible 137% increase from its Tuesday closing price of $38. The firm’s bullish outlook centers on CG Oncology’s advancements in bladder cancer treatment and a promising pipeline of new therapies.
Strong Buy Rating Driven by NMIBC Market Potential
A recent analysis highlighted CG Oncology’s strong position within the non-muscle invasive bladder cancer (NMIBC) industry. The company’s focus on developing innovative treatments for this specific cancer type has garnered attention from investors and analysts alike. Shares of CG Oncology have already demonstrated strong performance in 2025, increasing by 33% – significantly outpacing the S&P 500’s 14% gain during the same period.
Cretostimogene: A Potential Game-Changer
Central to Guggenheim’s optimistic assessment is the development of cretostimogene, an oncolytic immunotherapy. According to one analyst, “The nascent NMIBC drug market has lots of patients, industry pricing power, and long treatment durations, which makes the CGON story rise to the top of quality oncology ideas, in our view, given the best-in-class efficacy, durability and safety of cretostimogene, which will enter FDA review next year.”
This innovative therapy aims to provide a more durable and safer treatment option for NMIBC patients, many of whom undergo procedures to avoid more invasive surgeries like bladder removal (cystectomy). The analyst further explained that patients with this non-lethal form of cancer prioritize a drug with a “pristine drug safety profile,” a characteristic they believe cretostimogene possesses.
Catalyst Path and Analyst Consensus
CG Oncology is expected to benefit from a “potentially attractive catalyst path” over the next two years, with numerous data releases and regulatory updates anticipated. This positive outlook is reflected in the broader analyst community, with all 12 firms currently covering the stock assigning a buy or strong buy rating, according to data from LSEG.
The company’s advancements and promising pipeline position it as a key player in the evolving landscape of bladder cancer treatment, potentially driving substantial growth in the coming years.
